Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia
The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy regimen.
- Ages: 16 to 39
- Sexes: All
- Accepts healthy volunteers?: No
For additional eligibility criteria, please contact the study team.
This is a phase I study of the addition of pevonedistat to induction chemotherapy for AYA patients (16-39 years of age) with relapsed/refractory ALL utilizing a traditional 3+3 design with dose expansion cohort of 6 patients. Starting dose level for pevonedistat is 15 mg/m2.
If the number of dose-limiting toxicities (DLTs) is greater than 1 out of 3 patients in the starting dose level, next dose level is 10 mg/m2 (dose level -1). Chemotherapy will consist of pevonedistat in combination with a standard VXLD regimen. The duration of each cycle will be 29 days.
Contact the study team
Additional eligibility criteria and study procedure details can be explained by the study team. Please call or email:
KeywordsAcute lymphoblastic leukemia, Leukemia, Chronic lymphocytic leukemia, Chemotherapy
Principal InvestigatorWilliam Slayton, MD
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.